Go to main text
Go to main menu
IP Strategy Institute
MarkCare
main menu
About Us
Professionals
Practice Areas
News & Events
Contact Us
Careers
menu
KO
EN
Close
Professionals
Managing Partner
Professionals
Professionals
Young Il Lee
Patent Attorney / Partner
+82-2-6677-7603
yilee@jjpat.com
Practice Areas
Bio/Chemistry/Trademark/Design
Education and
Qualifications
B.S. in Pharmaceutical Sciences, Seoul National University
Passed the 37th Patent Attorney Examination (2000)
ICVS (International Certified Valuation Specialist) (2012)
Licensed Pharmacist (1998)
Career
Current)
Partner Patent Attorney, JUNGJIN Patent & Law Firm
Previous)
Patent Attorney, Lee International IP & Law Group
Partner Patent Attorney, WooIn Patent & Law Firm
Head of Patent Team, Hanwha Solutions Corporation (formerly Hanwha Chemical Corporation)
Head of Legal and IP Department, Genexine, Inc.
Patent Attorney, R&D Business Division, Asan Medical Center, Seoul
Head of R&BD Strategy and Planning Division, Wellmarker Bio Co., Ltd.
Head of Business Development Division, Recerise Therapeutics, Inc.
Bailiwick
Biotechnology / Pharmacy
Key achievements
Provided Korean published patent gazette domain services for Korean pharmaceutical companies to Israeli pharmaceutical company T
Advised the Korean Intellectual Property Office (KIPO) on the revision of examination guidelines in the pharmaceutical sector
Prepared a patent map for an antibody development project for domestic pharmaceutical company G
Conducted patent rights analysis for ETRI’s “Ubiquitous Health Monitoring System” project
Prepared a patent map for GIST’s seawater desalination technology development project
Developed a design-around strategy and handled a passive scope confirmation trial regarding a polymorph patent for Company H
Built a patent portfolio related to medical devices for Company C
Drafted a business execution plan and established a patent strategy for multi-component materials for the Gene Donguibogam Project Group
Conducted a technology valuation for new therapeutic uses of DPP-4 inhibitors for Foundation A and Company D
Performed a Freedom to Operate (FTO) analysis related to biosimilars for Company A
View members